In 2020, two other anti-CD19 mAbs received FDA approval including inebilizumab (Uplizna®), a humanized mAb used for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD), and tafasitamab (Monjuvi®), which is a humanized cytolytic mAb used for the treatment of adult patients with R/R diffuse large B-cell lymphoma (DLBCL) in combination with lenalidomide (Revlimid®) [6, 7]. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.